<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003364</url>
  </required_header>
  <id_info>
    <org_study_id>XCEL-SCI-01</org_study_id>
    <nct_id>NCT03003364</nct_id>
  </id_info>
  <brief_title>Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury</brief_title>
  <official_title>A Phase I/IIa, Randomized, Double-blind, Single-dose, Placebo Controlled, Two-way Crossover Clinical Trial to Assess the Safety and to Obtain Efficacy Data in Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de Neurorehabilitació Institut Guttmann</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Recerca Clínica S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syntax for Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/IIa, randomized, double-blind, single-dose, placebo controlled, two-way
      crossover clinical trial in which 10 patients from 18 to 65 years of age affected with
      chronic traumatic spinal cord will enter the study with the objective to assess the safety
      and to obtain efficacy data in intrathecal administration of expanded Wharton's jelly
      mesenchymal stem cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/IIa, randomized, double-blind, single-dose, placebo controlled, two-way
      crossover clinical trial in which 10 patients from 18 to 65 years of age affected with
      chronic traumatic spinal cord will enter the study with the objective to assess the safety
      and to obtain efficacy data in intrathecal administration (L3 level) of expanded Wharton's
      jelly mesenchymal stem cells. Following the administration patients will remain for 24 h at
      the hospital and thereafter will be discharged. For the first period, the follow-up is
      planned at day 7 and at 1, 3 and 6 months. At month 6, the patients will be treated in a
      crossover way (second period) and will follow the same schedule for the follow-up. Results
      will be initially assessed at 12 month follow-up and thereafter at 24 and 36 months as part
      of a long-term follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 27, 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent and severity of a patient's spinal cord injury</measure>
    <time_frame>6 months</time_frame>
    <description>ASIA Impairment Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor electrophysiology assessment</measure>
    <time_frame>6 month</time_frame>
    <description>Evoked potentials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatosensory electrophysiology assessment</measure>
    <time_frame>6 month</time_frame>
    <description>Evoked potentials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical nerve stimulation on pain perception</measure>
    <time_frame>6 month</time_frame>
    <description>Pain threshold perception</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mictional dysfunction</measure>
    <time_frame>6 month</time_frame>
    <description>Urodynamic testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anal sphincter integrity</measure>
    <time_frame>6 month</time_frame>
    <description>Anorectal manometry test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic pain</measure>
    <time_frame>6 months</time_frame>
    <description>Numerical scale (0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spasticity</measure>
    <time_frame>6 months</time_frame>
    <description>Modified Ashworth scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality</measure>
    <time_frame>6 months</time_frame>
    <description>SCIM III scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>WHOQOL-BREF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary disorder</measure>
    <time_frame>6 months</time_frame>
    <description>Qualiveen questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size injury</measure>
    <time_frame>12 months</time_frame>
    <description>Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of allogeneic cells</measure>
    <time_frame>1 month</time_frame>
    <description>Chimerism in cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology</measure>
    <time_frame>1 months</time_frame>
    <description>Antibodies anti-HLA in peripherical blood and in cerebrospinal fluid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Spinal Cord Injury, Chronic</condition>
  <arm_group>
    <arm_group_label>XCEL-UMC-BETA/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/XCEL-UMC-BETA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XCEL-UMC-BETA</intervention_name>
    <description>Intrathecal allogeneic cell therapy in a blinded syringe</description>
    <arm_group_label>XCEL-UMC-BETA/placebo</arm_group_label>
    <arm_group_label>Placebo/XCEL-UMC-BETA</arm_group_label>
    <other_name>Expanded MSC from Wharton Jelly</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in a blinded syringe</description>
    <arm_group_label>XCEL-UMC-BETA/placebo</arm_group_label>
    <arm_group_label>Placebo/XCEL-UMC-BETA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Single spinal cord injury lesion caused by trauma

          2. Affected cord segments between T2 and T11, confirmed by magnetic resonance

          3. Complete paraplegia (ASIA A)

          4. Chronic disease state (between 12 months and 5 years after the injury)

          5. Patients from 18 to 65 years of age, both sexes

          6. Life expectancy &gt; 2 years

          7. Confidence that the patient will attend the follow-up visits.

          8. Given informed consent in writing

          9. Patient is able to understand the study and its procedures

        Exclusion Criteria:

          1. Mechanic ventilation

          2. Lesion affecting multiple levels

          3. Lesion length superior to 3 spinal cord segments, assessed by magnetic resonance

          4. Penetrating trauma affecting the spinal cord

          5. Positive serology to HIV, HBV, HCV and or syphilis

          6. Pregnant woman or without proper anticonceptive measures according to the
             investigator, or breath feeding

          7. Use of metal implants that complicates the MRI interpretation

          8. Planned spinal surgery within subsequent 24 month after entering the trial

          9. Intrathecal medication or immunosuppressive drugs the previous 60 days.

         10. Neurodegenerative diseases

         11. Significant abnormal laboratory tests that contraindicates patient's participation in
             the study.

         12. Neoplasia within the previous 5 years, or without complete remission

         13. Patient with difficulty for communicating

         14. Participation in another clinical trial or treated with an investigational medicinal
             product the previous 60 days

         15. Contraindication for lumbar punction

         16. Other pathologic conditions or circumstances that could complicate the participation
             of the patient in the study according to medical criteria

         17. The patient does not accept to be followed-up for a period that could exceed the
             clinical trial length
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Vidal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Neurorehabilitació Institut Guttmann</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Neurorehabilitació Institut Guttmann</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://bancsang.net/en_index/</url>
    <description>Blood and Tissue Bank of Catalonia</description>
  </link>
  <link>
    <url>http://www.guttmann.com/en</url>
    <description>Hospital de Neurorehabilitació Institut Guttmann</description>
  </link>
  <link>
    <url>http://www.ccma.cat/tv3/marato/en/</url>
    <description>Marató TV3</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

